Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) Stock
Intersect ENT, Inc. (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $29.00, for a total value of $372,157.00. Following the completion of the sale, the chief financial officer now owns 27,833 shares in the company, valued at $807,157. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Intersect ENT, Inc. (NASDAQ:XENT) traded up 3.04% during trading on Monday, reaching $30.55. The company had a trading volume of 368,733 shares. The company’s 50 day moving average is $27.55 and its 200-day moving average is $20.21. Intersect ENT, Inc. has a 1-year low of $7.65 and a 1-year high of $30.65. The stock’s market capitalization is $884.42 million.
Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.11. The firm had revenue of $24 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.57%. The business’s quarterly revenue was up 24.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.21) earnings per share. On average, equities research analysts anticipate that Intersect ENT, Inc. will post ($0.63) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/07/jeryl-l-hilleman-sells-12833-shares-of-intersect-ent-inc-xent-stock.html.
Large investors have recently made changes to their positions in the stock. ClariVest Asset Management LLC acquired a new stake in Intersect ENT during the first quarter valued at approximately $148,000. Legal & General Group Plc raised its stake in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Intersect ENT by 109.1% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after buying an additional 6,000 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Intersect ENT during the second quarter valued at approximately $229,000. Finally, American International Group Inc. raised its stake in Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after buying an additional 1,037 shares during the last quarter. 76.11% of the stock is currently owned by hedge funds and other institutional investors.
XENT has been the topic of several research reports. Zacks Investment Research lowered Intersect ENT from a “hold” rating to a “strong sell” rating in a research note on Saturday, April 15th. Canaccord Genuity restated a “buy” rating and set a $32.00 target price on shares of Intersect ENT in a research report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 target price on Intersect ENT and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Northland Securities boosted their target price on Intersect ENT from $17.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, May 4th. Finally, ValuEngine upgraded Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $23.13.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.